UBS: Lilly’s Type 2 diabetes and obesity treatment could be ‘one of the best-selling drugs in history’


Shares of Eli Lilly & Co. Inc. LLY, +4.85% gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company’s newly approved Type 2 diabetes drug, could be “the biggest drug ever.” UBS analysts predict peak sales of $25 billion if the therapy is also approved as a treatment for weight management in people with obesity. “Tirzepatide’s robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see this being one of the best-selling drugs in history,” the analysts told investors in a note on Thursday. The Food and Drug Administration in May approved Mounjaro as Type 2 diabetes treatment, and Lilly is expected to file for approval of the same drug as a weight-management therapy after clinical research shared last spring showed that the drug helped people lose up to 22% of their body weight. Lilly’s stock is up 7.3% so far this year, while the broader S&P 500 SPX, -0.84% has declined 20.5%.

This article was originally published by Read the original article here.

Previous articleThe Margin: Boston Celtics coach Ime Udoka suspended for season for improper workplace relationship
Next articleU.S. stocks end lower as Treasury yields surge after Fed rate hike


Please enter your comment!
Please enter your name here